Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

White House Opposes Stand-Alone Medicare Rx Benefit – CMS’ Scully

Executive Summary

The Bush Administration will resist any Medicare prescription drug legislation that establishes a stand-alone benefit even if administered through private plans, Centers for Medicare & Medicaid Services Administrator Tom Scully said at a National Center for Policy Analysis briefing April 29

You may also be interested in...



CMS Proposed OPPS Rule Sets Reduced Payment Level During Generic Erosion

CMS' proposed 2004 Hospital Outpatient Prospective Payment System rule creates a payment level for drugs, biologics and radiopharmaceuticals with recently approved generic alternatives

CMS Proposed OPPS Rule Sets Reduced Payment Level During Generic Erosion

CMS' proposed 2004 Hospital Outpatient Prospective Payment System rule creates a payment level for drugs, biologics and radiopharmaceuticals with recently approved generic alternatives

Alternative GOP Medicare Rx Proposal Being Pushed By Rep. Burr

Rep. Richard Burr (R-N.C.) is leading an effort in the House to create a Medicare prescription drug package that could have a more realistic chance of passing both the House and the Senate than the GOP Medicare reform package being developed by the chairmen of the Ways & Means and Commerce Committees

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS041751

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel